Integrins, cell response to anti-tumor agents and chemoresistance;Intégrines, réponse cellulaire aux agents anticancéreux et chimiorésistance

Bulletin du Cancer

Volumn 89, Issue 11, 2002, Pages 923-934

  Maubant, Sylvie ^a   Staedel, Cathy ^b   Gauduchon, Pascal ^a  

^a UNIVERSITÉ DE CAEN   (France)

^b INSERM   (France)

Author keywords

Apoptosis; Chemoresistance; Integrins

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DOXORUBICIN; ETOPOSIDE; INTEGRIN; PAXILLIN; SCLEROPROTEIN;

APOPTOSIS; CANCER RESISTANCE; CANCER THERAPY; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; CYTOTOXICITY; HUMAN; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL ADHESION; CELL COMMUNICATION; CELL CYCLE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX PROTEINS; FOCAL ADHESION KINASE 1; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; INTEGRINS; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 17544387806     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Sherwood SW, Shimke RT. Cell cycle analysis of apoptosis using flow cytometry. In: Schwartz LM, Osborne BA, eds. Meth Cell Biol, vol. 46. Academic Press, 1995; 77-97.
2. Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochem 2000; 65: 96-106.
3. Robert J. Nouveaux concepts dans l'étude de la résistance aux médicaments anticancéreux. Bull Cancer 2002; 89: 17-22.
4. St Croix B, Kerbel RS. Cell adhesion and drug resistance in cancer. Curr Opin Oncol 1997; 9: 549-56.
5. Hynes RO. Integrins: A family of cell surface receptors. Cell 1987; 48: 549-54.
6. De Melker AA, Sonnenberg A. Integrins: Alternative splicing as a mechanism to regulate ligand binding and integrin signaling events. BioEssays 1999; 21: 499-509.
7. Velling T, Kusche-Gullberg M, Sejersen T, Gullberg D. cDNA cloning and chromosomal localization of human alpha(11) integrin: A collagen-binding, 1 domain-containing, beta(1)-associated integrin alpha-chain present in muscle tissues. J Biol Chem 1999; 274: 25735-42.
8. Drubin DG, Nelson WJ. Origins of cell polarity. Cell 1996; 84: 335-44.
9. Coppolino MG, Dedhar S. Bi-directional signal transduction by integrins receptors. Int J Biochem Cell Biol 2000; 32: 171-88.
10. Hemler ME. Integrin associated proteins. Curr Opin Cell Biol 1998; 10: 578-85.
11. Zamir E, Geiger B. Molecular complexity and dynamics of cell-matrix adhesions. J Cell Sci 2001; 114: 3583-90.
12. Schwartz MA, Baron V. Interactions between mitogenic stimuli, or, a thousand and one connections. Curr Opin Cell Biol 1999; 11: 197-202.
13. Rémy L, Bellaton C, Pourreyron C, Anderson W, Dumortier J, Jacquier MF. Intégrines et métalloprotéinase: Une collaboraton efficace dans le processus invasif. Bull Cancer 1999; 86: 154-8.
14. Howe A, Aplin AE, Alahari SK, Juliano RL. Integrin signaling and cell growth control. Curr Opin Cell Biol 1998; 10: 220-31.
15. Assoian RK. Anchorage-dependent cell cycle progression. J Cell Biol 1997; 136: 1-4.
16. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001; 13: 555-62.
17. Streuli C. Extracellular matrix remodelling and cellular differentiation. Curr Opin Cell Biol 1999; 11: 634-40.
18. Huttenlocher A, Ginsberg M, Horwitz A. Modulation of cell migration by integrin-mediated linkages and ligand-binding affinity. J Cell Biol 1996; 134: 1551-62.
19. Varner JA, Cheresh DA. Integrins and cancer. Curr Opin Cell Biol 1996; 8: 724-30.
20. Sage J. La famille du gène RB et le contrôle du cycle cellulaire. Bull Cancer 2001; 88: 541-3.
21. Brunet A. Transmission des signaux de la membrane vers le noyau: Variations sur des thèmes communs. Bull Cancer 1998; 85: 527-37.
22. Meredith JE, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993; 4: 953-71.
23. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994; 124: 619-26.
24. Zhang Z, Vuori K, Reed J, Ruoslahti E. The α5β1 integrin supports survival of cells on fibronectin and up-regulates bcl2 expression. Proc Natl Acad Sci USA 1995; 92: 6161-5.
25. Terui Y, Furukawa Y, Sakai T, Kikuchi J, Sugahara H, Kanakura Y, et al. Up-regulation of VLA-5 expression during monocytic differentiation and its role in negative control of the survival of petipheral blood monocytes. J Immunol 1996; 156: 1981-8.
26. Sato K, Katagiri K, Hattori S, Tsuji T, Irimura T, Irie S, et al. Laminin 5 promotes activation and apoptosis of T cells expressing α3β1 integrin. Exp Cell Res 1999; 247: 451-60.
27. Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM, Cheresh DA. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol 2001; 155: 459-70.
28. Schaller MD. Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochem Biophys Acta 2001; 1540: 1-21.
29. Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY. Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 1996; 134: 793-9.
30. FAK in cultured fibroblasts results in apoptosis. J Cell Biol 1996; 135: 1383-90.
31. Buttery PC, Mallawaarachchi CM, Milner R, Doherty P, Ffrench-Constant C. Mapping regions of the betal integrin cytoplasmic domain involved in migration and survival in primary oligodendrocyte precursors using cell-permeable homeopeptides. Biochem Biophys Res Commun 1999; 259: 121-7.
32. Xu LH, Owens LV, Sturge GC, Yang X, Liu ET, Craven RJ, et al. Attenuation of the expression of focal adhesion kinase induces apoptosis in tumor cells. Cell Growth Differ 1996; 7: 413-8.
33. Sonoda Y, Kasahara T, Yokota-Aizu E, Ueno M, Watanabe S. A suppressive role of p125FAK protein tyrosine kinase in hydrogen peroxide-induced apoptosis of T98G cells. Biochem Biophys Res Commun 1997; 241: 769-74.
34. Wen LP, Fahrni JA, Troie S, Guan JL, Orth K, Rosen GD. Cleavage of focal adhesion kinase by caspases during apoptosis. J Biol Chem 1997; 272: 26056-61.
35. FAK and disassembly of focal adhesions in human endothelial cell apoptosis. J Exp Med 1998; 187: 579-86.
36. Gervais FG, Thornberry NA, Ruffolo SC, Nicholson DW, Roy S. Caspases cleave focal adhesion kinase during apoptosis to generate a FRNK-like polypeptide. J Biol Chem 1998; 273: 17102-8.
37. Carragher NO, Levkau B, Ross R, Raines EW. Degraded collagen fragments promote rapid disassembly of smooth muscle focal adhesions that correlates with cleavage of pp125(FAK), paxillin, and talin. J Cell Biol 1999; 147: 619-30.
38. Ktasilnikov MA. Phosphatidylinositol-3 kinase dependent pathways: The role in control of cell growth, survival, and malignant transformation. Biochemistry 2000; 65: 59-67.
39. Sonoda Y, Watanabe S, Matsumoto Y, Aizu-Yokota E, Kasahara T. FAK is upstream signal protein of the phosphatidylinositol 3-kinase-Akt survival pathway in hydrogen peroxide-induced apoptosis of a human glioblastoma cell line. J Biol Chem 1999; 274: 10566-70.
40. Delcommene M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci USA 1998; 95: 11211-6.
41. Giancotti FG. Integrin signaling: Specificity and control of cell survival and cell cycle progression. Curr Opin Cell Biol 1997; 9: 691-700.
42. Ilic D, Almeida EA, Schlaepfer DD, Dazin P, Aizawa S, Damsky CH. Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis. J Cell Biol 1998 143: 547-60.
43. Le Gall M, Chambard JC, Breittmayer JP, Grall D, Pouyssegur J, Van Obberghen-Schilling E. The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal. Mol Biol Cell 2000; 11: 1103-12.
44. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998; 10: 262-7.
45. Reed JC. Regulation of apoptosis by bcl2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995; 7: 541-6.
46. Bettaieb A, Sordet O, Belon JP, Solary E. Apoptose et chimiothérapie. Bull Cancer 1999; 86: 41-6.
47. Bozzo C, Bellomo G, Silengo L, Tarone G, Altruda F. Soluble integrin ligands and growth factors indepently rescue neuroblastoma cells from apoptosis under nonadherent conditions. Exp Cell Res 1997; 237: 326-37.
48. Petitclerc E, Stromblad S, von Schalscha TL, Mitjans F, Piulats J, Montgomery AM, et al. Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res 1999; 59: 2724-30.
49. Gilmore AP, Metcalfe AD, Romer LH, Streuli CH. Integrin-mediated survival signals regulate the apoptotic function of bax through its conformation and subcellular localization. J Cell Biol 2000; 149: 431-46.
50. Hainaut P. Le géne suppresseur de tumeurs TP53: Vingt ans (et dix mille mutations) après. Bull Cancer 2000; 87: 11-8.
51. Boudreau N, Sympson CJ, Werb Z, Bissell MJ. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 1995; 267: 891-3.
52. Bachelder RE, Ribick MJ, Marchetti A, Falcioni R, Soddu S, Davis KR, et al. p53 inhibits alpha 6 beta 4 integrin survival signaling by promoting the caspase 3-dependent cleavage of AKT/PKB. J Cell Biol 1999; 147: 1063-72.
53. WAF1/CIP1 expression by vascular cell integrin αvβ3 during angiogenesis. J Clin Invest 1996; 98: 426-33.
54. waf1 pathway in response to disruption of cell-matrix intercations. J Biol Chem 1997; 272: 29091-8.
55. Bachelder RE, Marchetti A, Falcioni R, Soddu S, Mercurio AM. Activation of p53 function in carcinoma cells by the alpha6beta4 integrin. J Biol Chem 1999; 274: 20733-7.
56. Lewis JMA, Truong TN, Schwartz MA. Integrins modulate the apoptotic response to DNA damage through modulation of p53. PNAS 2002; 99: 3627-32.
57. Adderley SR, Fitzgerald DJ. Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation. J Biol Chem 2000; 275: 5760-6.
58. Buckley CD, Pilling D, Henriquez NV, Parsonage G, Threlfall K, Scheel-Toellner D, et al. RGD peptides induce apoptosis by direct cas-pase-3 activation. Nature 1999; 397: 534-9.
59. Frisch SM. Evidence for a function of death-receptor-related, deathdomain-containing proteins in anoikis. Curr Biol 1999; 9: 1047-9.
60. Rytomaa M, Martins LM, Downward J. Involvement of FADD and caspase-8 signalling in detachment-induced apoptosis. Curr Biol 1999; 9: 1043-6.
61. Garrington TP, Johnson GL. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 1999; 11: 211-8.
62. Frisch SM, Vuori K, Kelaita D, Sicks S. A role for jun-N-terminal kinase in anoikis: Suppression by bcl2 and crmA. J Cell Biol 1996; 135: 1377-82.
63. Cardone MH, Salvesen GS, Widmann C, Johnson G, Frisch SM. The regulation of anoikis: MEKK-1 activation requires cleavage by caspases. Cell 1997; 90: 315-23.
64. Almeida EA, Ilic D, Han Q, Hauck CR, Jin F, Kawakatsu H, et al. Matrix survival signaling. From fibronectin via focal adhesion kinase to c-jun nh(2)-terminal kinase. J Cell Biol 2000; 149: 741-54.
65. Day ML, Foster RG, Day KC, Zhao X, Humphrey P, Swanson P, et al. Cell anchorage regulates apoptosis through the retinoblastoma tumor suppressor/E2F pathway. J Biol Chem 1997; 272: 8125-8.
66. Plath T, Detjen K, Welzel M, von Marschall Z, Murphy D, Schirner M, et al. A novel function for the tumor suppressor p16(INK4a): Induction of anoikis via upregulation of the alpha(5)beta(1) fibronectin receptor. J Cell Biol 2000; 150: 1467-78.
67. Hazlehurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM, et al. Reduction in drug-induced DNA double-strand breaks associated with betal integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 2001; 98: 1897-903.
68. Taylor ST, Hickman JA, Dive C. Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors. J Natl Cancer Inst 2000; 92: 18-23.
69. Aoudjit F, Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001; 20: 4995-5004.
70. Huang S, Ingber DE. The structural and mechanical complexity of cell growth control. Nature Cell Biology 1999; 1: E131-E138.
71. Hoyt DG, Rusnak JM, Mannix RJ, Modzelewski RA, Johnson CS, Lazo JS. Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells. Cancer Res 1996; 56: 4146-9.
72. Uhm JH, Dooley NP, Kyritsis AP, Rao JS, Gladson CL. Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clin Cancer Res 1999; 5: 1587-94.
73. Kouniavsky G, Khaikin M, Zvibel I, Zippel D, Brill S, Halpern Z, et al. Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines. Clin Exp Metastasis 2002; 19: 55-60.
74. Damiano JS, Dalton WS. Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma 2000; 38: 71-81.
75. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nature Med 1999; 5: 662-8.
76. Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000; 19: 4319-27.
77. FAK) in invasive human tumors. Cancer Res 1995; 55: 2752-5.
78. Weyant MJ, Carothers AM, Bertagnolli ME, Bertagnolli MM. Colon cancer chemopreventive drugs modulate integrin-mediated signaling pathways. Clin Cancer Res 2000; 6: 949-56.
79. Chauffert B, Correia M, Sergent C. Actualités sur les mécanismes de la chimiorésistance. Bull Cancer 1999; 86: 97-103.
80. Nista A, Leonetti C, Bernardini G, Mattioni M, Santoni A. Functional role of α4β1 and α5β1 integrin flbronectin receptors expressed on adriamycin-resistant MCF-7 human mammary carcinoma cells. Int J Cancer 1997; 72: 133-41.
81. Narita T, Kimur N, Sato M, Matsuura N, Kannagi R. Altered expression of integrins in adriamycin-resistant human breast cancer cells. Anticancer Res 1998; 18: 257-62.
82. Sedlak J, McGown A, Hrubisko M, Hunakova L, Chorvath B. Drug-resistance associated alterations of cell surface antigen expression in a human anthracycline-resistant ovarian carcinoma cell line. Neoplasma 1994; 41: 259-62.
83. Sedlak J, Sedlakova O, Hlavcak P, Hunakova L, Bizik J, Grofova M, et al. Cell surface phenotype and increased penetration of human multi-drug-resistant ovarian carcinoma cells into in vitro collagen-fibroblasts matrix. Neoplasma 1996; 43: 389-95.
84. Duensing S, Brevis Nunez F, Meyer N, Anastassiou G, Nasarek A, Crosse J, et al. Exposure to vinblastine modulates beta 1 integrin expression and in vitro binding to extracellular matrix molecules in a human renal carcinoma cell line. Invasion Metastasis 1996; 16: 65-72.
85. Meyer N, Duensing S, Anastassiou G, Brevis Nunez F, Crosse J, Ganser A, et al. Altered expression of beta 1 integrins in renal carcinoma cell lines exposed to vinblastine. Anticancer Res 1999; 19: 1509-12.
86. Liang Y, Meleady P, Cleary I, McDonnell S, Connolly L, Clynes M. Selection with melphalan or paclitaxel (Taxol) yields variants with different patterns of multidrug resistance, integrin expression and in vitro invasiveness. Eur J Cancer 2001; 37: 1041-52.
87. Poulain L, Lincet H, Duigou F, Deslandes E, Sichel F, Gauduchon P, et al. Acquisition of chemoresistance in a human ovarian carcinoma cell line is linked to a defect in cell-cyde control. Int J Cancer 1998; 78: 454-63.
88. Maubant S, Cruet-Hennequart S, Poulain L, Carreiras F, Sichel F, Luis J, et al. Altered adhesion properties and alpha v integrin expression in a cisplatin-resistant human ovarian carcinoma cell line. Int J Cancer 2002; 97: 186-94.
89. Bottger TC, Maschek H, Lobo M, Gottwohl RG, Brenner W, Junginger T. Prognostic value of immunohistochemical expression of beta-1 integrin in pancreatic carcinoma. Oncology 1999; 56: 308-13.
90. Vihinen P, Nikkola J, Vlaykova T, Hahka-Kemppinen M, Talve L, Heino J, et al. Prognostic value of beta1 integrin expression in metastatic melanoma. Melanoma Res 2000; 10: 243-51.
91. Lindmark G, Gerdin B, Pahlman L, Glimelius B, Gehlsen K, Rubin K. Interconnection of integrins alpha 2 and alpha 3 and structure of the basal membrane in colorectal cancer: Relation to survival. Eur J Surg Oncol 1993; 19: 50-60.
92. Adachi M, Taki T, Huang C, Higashiyama M, Doi O, Tsuji T, et al. Reduced integrin alpha3 expression as a factor of poor prognosis of patients with adenocarcinoma of the lung. J Clin Oncol 1998; 16: 1060-7.
93. Adachi M, Taki T, Higashiyama M, Kohno N, Inufusa H, Miyake M. Significance of integrin alpha5 gene expression as a prognostic factor in node-negative non-small cell lung cancer. Clin Cancer Res 2000; 6: 96-101.
94. Tagliabue E, Ghirelli C, Squicciarini P, Aiello P, Colnaghi MI, Menard S. Prognostic value of alpha 6 beta 4 integrin expression in breast carcinomas is affected by laminin production from tumor cells. Clin Cancer Res 1998; 4: 407-10.
95. Grossman HB, Lee C, Bromberg J, Liebert M. Expression of the alpha6beta4 integrin provides prognostic information in bladder cancer. Oncol Rep 2000; 7: 13-6.
96. Hieken TJ, Farolan M, Ronan SG, Shilkaitis A, Wild L, Das Gupta TK. Beta3 integrin expression in melanoma predicts subsequent metastasis. J Surg Res 1996; 63: 169-73.
97. Carreiras F, Denoux Y, Staedel C, Lehmann M, Sichel F, Gauduchon P. Expression and localisation of αv integrins and of their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Gynecol Oncol 1996; 62: 260-7.
98. Goldberg I, Davidson B, Reich R, Gotlieb WH, Ben-Baruch G, Bryne M, et al. Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma. Clin Cancer Res 2001; 7: 4073-9.
99. Liapis H, Adler LM, Wick MR, Rader JS. Expression of αvβ3 integrin is less frequent in ovarian epithelial tumours of low malignant potential in contrast to ovarian carcinoma. Hum Path 1997; 28: 443-9.
100. Muller-Klingspor V, Hefler L, Obermair A, Kaider A, Breitenecker G, Leodolte S, et al. Prognostic value of betal-integrin (= CD29) in serous adenocarcinomas of the ovary. Anticancer Res 2001; 21: 2185-8.
101. Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, et al. Differential expression of MMAC/PTEN in glioblastoma multiforme: Relationship to localization and prognosis. Cancer Res 1999; 59: 1820-4.
102. Graff JR, Deddens JA, Konicek BW, Colligan BM, Hurst BM, Carter HW, et al. Integrin-linked kinase expression increases with prostate tumor grade. Clin Cancer Res 2001; 7: 1987-91.